SBIO.L vs. HLTW.L
SBIO.L (Invesco Nasdaq Biotech UCITS ETF) and HLTW.L (Lyxor UCITS MSCI World Health Care TR C-USD) are both Health & Biotech Equities funds - SBIO.L tracks the NASDAQ Biotechnology TR USD while HLTW.L tracks the MSCI World/Health Care NR USD. Both are passively managed. Over the past 10 years, SBIO.L returned 7.49%/yr vs 7.69%/yr for HLTW.L. A 0.74 correlation means they provide meaningful diversification when combined. SBIO.L charges 0.40%/yr vs 0.30%/yr for HLTW.L.
Performance
SBIO.L vs. HLTW.L - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, SBIO.L achieves a 4.34% return, which is significantly higher than HLTW.L's -3.12% return. Both investments have delivered pretty close results over the past 10 years, with SBIO.L having a 7.49% annualized return and HLTW.L not far ahead at 7.69%.
SBIO.L
- 1D
- 3.10%
- 1M
- -0.64%
- YTD
- 4.34%
- 6M
- 3.70%
- 1Y
- 41.44%
- 3Y*
- 12.99%
- 5Y*
- 4.66%
- 10Y*
- 7.49%
HLTW.L
- 1D
- 3.02%
- 1M
- 1.93%
- YTD
- -3.12%
- 6M
- -1.75%
- 1Y
- 11.48%
- 3Y*
- 5.29%
- 5Y*
- 4.29%
- 10Y*
- 7.69%
SBIO.L vs. HLTW.L - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
SBIO.L Invesco Nasdaq Biotech UCITS ETF | 4.34% | 32.89% | -2.00% | 6.14% | -11.85% | -0.49% | 27.35% | 25.54% | -11.34% | 21.45% |
HLTW.L Lyxor UCITS MSCI World Health Care TR C-USD | -3.12% | 15.73% | 0.39% | 3.08% | -5.66% | 20.58% | 12.94% | 22.85% | 1.54% | 20.11% |
Correlation
The correlation between SBIO.L and HLTW.L is 0.72, which is moderate. They share some common price drivers but move independently often enough to provide real diversification benefit when combined.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.72 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.69 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.70 |
Correlation (10Y) Calculated over the trailing 10-year period | 0.72 |
Correlation (All Time) Calculated using the full available price history since Nov 10, 2014 | 0.74 |
The correlation between SBIO.L and HLTW.L has been stable across timeframes, ranging from 0.69 to 0.74 - a consistent structural relationship.
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
SBIO.L vs. HLTW.L — Risk / Return Rank
SBIO.L
HLTW.L
SBIO.L vs. HLTW.L - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Invesco Nasdaq Biotech UCITS ETF (SBIO.L) and Lyxor UCITS MSCI World Health Care TR C-USD (HLTW.L). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| SBIO.L | HLTW.L | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +1.30 | ||
| Sortino ratioReturn per unit of downside risk | +1.71 | ||
| Omega ratioGain probability vs. loss probability | 1.35 | 1.15 | +0.20 |
| Calmar ratioReturn relative to maximum drawdown | 5.38 | 1.14 | +4.25 |
| Martin ratioReturn relative to average drawdown | 16.56 | 2.84 | +13.72 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading charts...
Sharpe Ratios by Period
| SBIO.L | HLTW.L | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | 2.09 | 0.79 | +1.30 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | 0.22 | 0.30 | -0.08 |
Sharpe Ratio (10Y)Calculated over the trailing 10-year period | 0.34 | 0.52 | -0.18 |
Sharpe Ratio (All Time)Calculated using the full available price history | 0.27 | 0.75 | -0.49 |
Drawdowns
SBIO.L vs. HLTW.L - Drawdown Comparison
The maximum SBIO.L drawdown since its inception was -39.44%, which is greater than HLTW.L's maximum drawdown of -26.58%. Use the drawdown chart below to compare losses from any high point for SBIO.L and HLTW.L.
Loading charts...
Drawdown Indicators
| SBIO.L | HLTW.L | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -39.44% | -26.58% | -12.86% |
Max Drawdown (1Y)Largest decline over 1 year | -7.64% | -10.12% | +2.48% |
Max Drawdown (3Y)Largest decline over 3 years | -26.88% | -19.19% | -7.69% |
Max Drawdown (5Y)Largest decline over 5 years | -38.33% | -19.19% | -19.14% |
Max Drawdown (10Y)Largest decline over 10 years | -38.33% | -26.58% | -11.75% |
Current DrawdownCurrent decline from peak | -2.84% | -5.90% | +3.06% |
Average DrawdownAverage peak-to-trough decline | -16.83% | -5.20% | -11.63% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 2.49% | 4.06% | -1.57% |
Volatility
SBIO.L vs. HLTW.L - Volatility Comparison
Invesco Nasdaq Biotech UCITS ETF (SBIO.L) has a higher volatility of 6.55% compared to Lyxor UCITS MSCI World Health Care TR C-USD (HLTW.L) at 4.82%. This indicates that SBIO.L's price experiences larger fluctuations and is considered to be riskier than HLTW.L based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| SBIO.L | HLTW.L | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 6.55% | 4.82% | +1.73% |
Volatility (6M)Calculated over the trailing 6-month period | 15.27% | 10.63% | +4.64% |
Volatility (1Y)Calculated over the trailing 1-year period | 19.67% | 14.52% | +5.15% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 21.21% | 14.16% | +7.05% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 22.23% | 14.85% | +7.38% |
SBIO.L vs. HLTW.L - Expense Ratio Comparison
SBIO.L has a 0.40% expense ratio, which is higher than HLTW.L's 0.30% expense ratio.
Dividends
SBIO.L vs. HLTW.L - Dividend Comparison
Neither SBIO.L nor HLTW.L has paid dividends to shareholders.
Frequently Asked Questions
SBIO.L and HLTW.L have a correlation of 0.72, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
On fees, HLTW.L is cheaper at 0.30% per year. The better choice depends on whether you care most about return, fees, risk, or income.
HLTW.L is cheaper with a 0.30% expense ratio, compared with 0.40% for SBIO.L.
SBIO.L tracks NASDAQ Biotechnology TR USD, while HLTW.L tracks MSCI World/Health Care NR USD. They also come from different issuers: Invesco and Amundi. Their fees differ too: 0.40% for SBIO.L and 0.30% for HLTW.L.
Find the right allocation for SBIO.L and HLTW.L
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer